Trial reportJournal of the Royal Society, Interface2013
Modelling HIV-1 2-LTR dynamics following raltegravir intensification.
Trial report in Journal of the Royal Society, Interface, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected Individuals.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Dynamics of natural and pharmacologic control of an SIV variant with an envelope trafficking defect.The Journal of experimental medicine · 2026Article
- Cardiac and Renal Comorbidities in Aging People Living With HIV.Circulation research · 2024Review
- Estimating the contribution of CD4 T cell subset proliferation and differentiation to HIV persistence.Nature communications · 2023Article
- The Many Faces of Immune Activation in HIV-1 Infection: A Multifactorial Interconnection.Biomedicines · 2023Review
- Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01.Frontiers in immunology · 2021Article
- Next-Generation Sequencing in a Direct Model of HIV Infection Reveals Important Parallels to and Differences fromJournal of virology · 2020Article
- An Integrated Spatial Dynamics-Pharmacokinetic Model Explaining Poor Penetration of Anti-retroviral Drugs in Lymph Nodes.Frontiers in bioengineering and biotechnology · 2020Article
- Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms.Frontiers in microbiology · 2019Review
- Modeling HIV persistence and cure studies.Current opinion in HIV and AIDS · 2018Review
- Dynamics of Simian Immunodeficiency Virus Two-Long-Terminal-Repeat Circles in the Presence and Absence of CD8Journal of virology · 2018Article
- Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence.Retrovirology · 2018Review
- HIV 2-LTR experiment design optimization.PloS one · 2018Article
- Implications of Measurement Assay Type in Design of HIV Experiments.Proceedings of the ... IEEE Conference on Decision & Control. IEEE Conference on Decision & Control · 2017Article
- Experiment Design for Early Molecular Events in HIV Infection.Proceedings of the ... American Control Conference. American Control Conference · 2017Article
- Order preservation of expected information content using Unscented Transform approximation of multivariate prior distributions in HIV 2-LTR experiment design.Proceedings of the ... IEEE Conference on Decision & Control. IEEE Conference on Decision & Control · 2016Article
- Increased inflammation in sanctuary sites may explain viral blips in HIV infection.IET systems biology · 2016Article
- Persistent HIV-1 replication during antiretroviral therapy.Current opinion in HIV and AIDS · 2016Review
- Prospective HIV Clinical Trial Comparison by Expected Kullback-Leibler Divergence.Proceedings of the ... American Control Conference. American Control Conference · 2016Article
- Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.PLoS pathogens · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A model of reservoir activation and viral replication is introduced accounting for the production of 2-LTR HIV-1 DNA circles following antiviral intensification with the HIV integrase inhibitor raltegravir, considering contributions of de novo infection events and exogenous sources of infected cells, including quiescent infected cell activation. The model shows that a monotonic increase in measured 2-LTR concentration post intensification is consistent with limited de novo infection primarily maintained by sources of infected cells unaffected by raltegravir, such as quiescent cell activation, while a transient increase in measured 2-LTR concentration is consistent with significant levels of efficient (R0 > 1) de novo infection. The model is validated against patient data from the INTEGRAL study and is shown to have a statistically significant fit relative to the null hypothesis of random measurement variation about a mean. We obtain estimates and confidence intervals for the model parameters, including 2-LTR half-life. Seven of the 13 patients with detectable 2-LTR concentrations from the INTEGRAL study have measured 2-LTR dynamics consistent with significant levels of efficient replication of the virus prior to treatment intensification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.